ClinicalTrials.gg
RecruitingNCT06802835Updated May 11, 2026

EGFR Antibody Combined With PD-1 Inhibitor and Chemotherapy in R/M Nasopharyngeal Carcinoma

A Phase 1/2 interventional study of EGFR Antibody and PD-1 antibody in Nasopharyngeal Cancinoma (NPC), Recurrent Nasopharynx Carcinoma and Metastatic Nasopharyngeal Carcinoma, sponsored by Sun Yat-sen University. Recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-05-11.

Primary conditionNasopharyngeal CarcinomaRegistry: Nasopharyngeal NeoplasmsReclassifiedWhy we changed it
Registry
Nasopharyngeal Neoplasms — the first condition term the registry derived for this study.
ClinicalTrials.gg
Nasopharyngeal Carcinoma
Why
  1. The study's listed conditions name Nasopharyngeal Carcinoma, a narrower term within Nasopharyngeal Neoplasms.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Sun Yat-sen University · Phase 1/2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jul 2025; still recruiting 1 year 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
148
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 140 studies testing Immune checkpoint inhibitors in Nasopharyngeal Carcinoma — 73 open to participants now, 98 under way, 27 of them phase 3. A drug class: Immune checkpoint inhibitors · Nasopharyngeal Carcinoma.

Planned enrollment
51st of 140
148 · median 75
Started
2025
with 15 others
Phase 1/2
7 of 140
5 open now
Primary completion
2027-06
later than 60 of 97 live
Registered
115th of 140
by date
Lead sponsor
44 of 140
Sun Yat-sen University

Among the 140 studies testing Immune checkpoint inhibitors in Nasopharyngeal Carcinoma, this one is the 51st largest by planned enrollment, is one of 16 that started in 2025, is one of 7 in phase 1/2, reaches primary completion later than 60 of the 97 other live ones, and was the 115th registered.

Nasopharyngeal Carcinoma

683 studies on the registry are indexed under Nasopharyngeal Carcinoma; 270 are open to participants now.

Browse Nasopharyngeal Carcinoma studies →

Open to participants now

73 of the 140 studies testing Immune checkpoint inhibitors in Nasopharyngeal Carcinoma are open now, in 9 countries. Recruiting first, the newest first:

67 more — sign in →

By country, each count listing its studies:

All 73 open studies →

About Immune checkpoint inhibitors

A class of medicines: which ones, and the studies of each, are on its page →

Who these studies take

Of the 186 Nasopharyngeal Carcinoma studies recruiting now, 42 (23%) set no upper age limit and 135 (73%) stop at 75 or younger; 9 take children under 18; 8 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 140 studies testing Immune checkpoint inhibitors in Nasopharyngeal Carcinoma, or all of them as a file.
02

Study summary

This is a prospective, single-arm, phase II clinical trial. The purpose of this study is to evaluate the efficacy and adverse effect of EGFR antibody combined with programmed death 1 (PD-1) antibody and chemotherapy in recurrent/metastatic nasopharyngeal carcinoma patients.

03

Conditions studied

  • Nasopharyngeal Cancinoma (NPC)
  • Recurrent Nasopharynx Carcinoma
  • Metastatic Nasopharyngeal Carcinoma

Browse trials for

Keywords

  • EGFR antibody
  • PD-1 antibody
  • chemotherapy
04

In context

Nasopharyngeal Carcinoma Reclassified

683 studies on the registry are indexed under Nasopharyngeal Carcinoma; 270 are open to participants now.

This study's planned enrollment of 148 is above the median of 100 across 557 interventional studies indexed under Nasopharyngeal Carcinoma.

Browse Nasopharyngeal Carcinoma studies →

Lead sponsor

Sun Yat-sen University is the lead sponsor of 1,695 studies on the registry; 622 are open to participants now.

Compared within Nasopharyngeal Carcinoma, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Nasopharyngeal Neoplasms. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with nasopharyngeal carcinoma who have recurred/metastasized after initial treatment or radical treatment;
  • Age 18-75, male or female;
  • Pathological diagnosis of nasopharyngeal carcinoma;
  • score 0-1;
  • Have not previously received any anti-tumor therapy such as radiotherapy, chemotherapy, immunotherapy or biotherapy for recurrence/;
  • No of chemotherapy, immunotherapy and targeted therapy;
  • At least 1 that meets 1.1 criteria;
  • Blood routine examination standards should meet: WBC≥3.0×109/L, ≥1.5×109/L, ≥100×109/L, HGB≥90g/L (no blood transfusion and blood products within 14 days, no G-CSF and other hematopoietic stimulating factors are used to correct);
  • Biochemical tests should meet the following criteria: ≤2.0×, , AST≤2.5×ULN, BUN and CRE≤1.5×ULN or endogenous ≥60ml/min (Cockcroft-Gault formula);
  • Good coagulation function: defined as International standardized ratio () or prothrombin time (PT) ≤1.5 times ULN; If the subject is receiving anticoagulant therapy, as long as PT is within the intended range of anticoagulant drug use;
  • The myocardial enzyme spectra were in the normal range;
  • Women of childbearing age must already be using reliable or have had a pregnancy test (serum or urine) within 7 days of enrollment with a negative result and be willing to use an effective method of contraception during the trial and for 3 months after the last antibody administration. For male subjects whose partners are women of reproductive age, effective contraception should be used during the trial and within 3 months after the last anti-PD-1 antibody administration;
  • The subjects voluntarily joined the study, signed , had good compliance, and cooperated with follow-up;

Exclusion criteria

Exclusion Criteria:

  • Patients with recurrence who can be treated with local resection or radiotherapy;
  • Known to be allergic to the drug or any thereof, or has had a severe allergic reaction to other monoclonal antibodies;
  • Patients have symptoms of central nervous system such as brain edema and need hormonal intervention;
  • Had an active infection or unexplained fever >38.5℃ during screening or prior to the first dose (the investigator determined that the subject's fever due to the tumor could be enrolled);
  • Have any active disease or history of autoimmune disease (e.g., interstitial pneumonia, uveitis, enteritis, hepatitis, hypophysitis, vasculitis, myocarditis, nephritis, hyperthyroidism, hypothyroidism [may be included after normal hormone replacement therapy]); Patients with vitiligo or complete remission of asthma in childhood without any intervention as adults could be included, but patients with asthma requiring medical intervention with bronchodilators could not be included;
  • Have congenital or acquired immunodeficiency (such as ), active (HBV-DNA≥103 copy number /ml), or (hepatitis C antibody positive and HCR-RNA above the lower detection limit of analytical methods);
  • Previous or co-existing uncured , except cured basal cell carcinoma of the skin, carcinoma in situ of the cervix and superficial bladder cancer;
  • Uncontrolled cardiovascular disease: Grade II or higher myocardial ischemia or myocardial infarction, poorly controlled arrhythmias (including ≥470 ms); Patients with grade III-IV cardiac insufficiency according to standards, or (LVEF) \<50% indicated by cardiac color ultrasound; Myocardial infarction within 1 year;
  • If the subject has undergone major surgery, the toxic effects and/or complications of the surgical intervention must be fully recovered before treatment is initiated;
  • Within 4 weeks prior to the first use of the investigational drug (participants in the follow-up period are counted as the last use of the investigational drug or device) or are currently participating in another clinical study;
  • received within 4 weeks prior to the first administration of the investigational drug is allowed to receive inactivated virus vaccine for seasonal influenza by injection, but not live attenuated influenza vaccine for nasal administration;
  • Pregnant or lactating women;
  • In the investigator's judgment, the subjects had other factors that might have led to their forced discontinuation of the study, such as other serious medical conditions (including mental illness) requiring concomitant treatment, serious abnormalities in laboratory test values, or family or social factors that might have affected the safety of the subjects or the circumstances of the trial data collection.
Terms in these criteria, in plain language(26)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

06

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
148 participants (estimated)

Study arms

  • Experimental
    EGFR+PD-1+Chemo

    Drug: EGFR Antibody · Drug: PD-1 antibody · Drug: Gemcitabine, Cisplatin · Radiation: IMRT

Interventions

07

What researchers measure

Primary outcomes

  1. Progression-free survival (PFS)

    From the date of recruiting to the first occurrence of disease progression as determined according to RECIST v1.1 or death from any cause, whichever occurs first.

    Time frame: 1 year

Secondary outcomes

  1. Adverse events

    All adverse event or serious adverse event that occurred during the study period according to CTCAE v 5.0.

    Time frame: Up to 16 months

  2. Overall survival (OS)

    From the date of recruiting to the date of death from any cause.

    Time frame: 1 year

  3. Objective response rate (ORR)

    The percentage of patients with CR and PR assessed according to RECIST v1.1.

    Time frame: 1 year

  4. Disease control rate (DCR)

    The proportion of patients who have achieved complete response, partial response and stable disease according to RECIST v1.1.

    Time frame: 1 year

  5. Quality of life (QoL)

    Assessed by EQ-5D-5L questionnaire

    Time frame: 1 year

08

Study locations

1 of 1 sites recruiting
09

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jul 2025 (actual). Primary completion is estimated for Jun 2027, 23 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 25, 2025
First posted
Jan 31, 2025
StartActual
Jul 9, 2025
Primary completionEst.
Jun 2027
CompletionEst.
Jun 2029
Last update
May 11, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 11, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT06802835
Collaborators
Zhejiang Cancer Hospital, Wuhan TongJi Hospital, Xijing hospital of The fourth military medical university, Dongguan People's Hospital, Liuzhou Workers' Hospital, Chongqing University Cancer Hospital, Second Affiliated Hospital, School of Medicine, Zhejiang University, Jiangxi Provincial Cancer Hospital, Fujian Province Tumor Hospital, First Affiliated Hospital of Guangxi Medical University
Responsible party
Zhao Chong (Prof., Sun Yat-sen University) — Principal investigator
First posted
Jan 31, 2025
Start date
Jul 9, 2025
Primary completion
Jun 2027 (estimated)
Completion
Jun 2029 (estimated)
Last update
May 11, 2026

Study contacts

Zhao Chong PhD.
Contact
zhaochong@sysucc.org.cn
139022061610
Miao Jingjing MD.
Contact
miaojj@sysucc.org.cn
13631355201

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: EGFR Antibody · Immune checkpoint inhibitors

Start the discussion